Atom Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Atom Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,260	Closed	-$214K	–	592
2025 Q3	$214K	Buy	+28,260	New	+$235K	0.02%	503
2021 Q1	–	Sell	-32,453	Closed	-$242K	–	256
2020 Q4	$242K	Buy	32,453 +17,653	+119%	+$91K	0.02%	294
2020 Q3	$51K	Buy	+14,800	New	+$63.4K	﹤0.01%	494

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Atom Investors's BCRX Position: Q4 2025 in Review

Atom Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 28,260 shares — an estimated $214K sold.

Atom Investors first reported a position in BCRX in Q3 2020 and held it in 3 quarters. The position peaked at $242K in Q4 2020. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Atom Investors reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 28,260 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $214K.
Atom Investors first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 3 quarters.
Atom Investors's BioCryst Pharmaceuticals position peaked at $242K in Q4 2020.
273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.